Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059644 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
A Phase 3 study, sponsored by Tanabe Pharma Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT00059644: Clinical Trial Phase 3 study, sponsored by Tanabe Pharma Corporation.
NCT00059644 is a Phase 3 study that was terminated before completion, run by Tanabe Pharma Corporation. The registered enrollment target is 560 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059644, a Phase 3 study, was terminated before completion, sponsored by Tanabe Pharma Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
Interventions
- DRUG Ecraprost in lipid emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2001-07 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Why NCT00059644 stopped before completion
NCT00059644 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 1 intervention - of which Ecraprost in lipid emulsion is the first listed.
NCT00059644 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00059644 about?
NCT00059644 is a clinical study titled "Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease". Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
What is the current status of trial NCT00059644?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2001-07. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00059644?
The interventions under investigation include: Ecraprost in lipid emulsion (DRUG).
Who is sponsoring clinical trial NCT00059644?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00059644's enrollment target sits among peer trials
560 671st of 2000 higher than 1,328 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia